| AIMT Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the AIMT shares outstanding history going back to 8/6/2015:
Also see: AIMT Market Cap History AIMT YTD Return |
AIMT Shares Outstanding History — Aimmune Therapeutics Share Count Over Time
As of 7/24/2020 Aimmune Therapeutics has 65.45 million AIMT shares outstanding. Investors often track the AIMT shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows AIMT share count trends over time, with 23 historical shares outstanding datapoints presented, dating back to 8/6/2015.
| AIMT Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||
AIMT Historical Shares Outstanding: +10.97% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||
| AIMT Stock Price Chart |
| About Aimmune Therapeutics Inc |
| Aimmune Therapeutics is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. Co.'s main therapeutic approach, which it refers to as Characterized Oral Desensitized Immunology Therapy (CODIT™), is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure or reduce symptom severity should an allergic reaction occur. PALFORZIA™ (Peanut (Arachis hypogaea) Allergen Powder-dnfp) is Co.'s internally developed product utilizing CODIT and has been approved by the U.S. Food and Drug Administration and it is indicated for the mitigation of allergic reactions. We show 23 historical shares outstanding datapoints in our coverage of AIMT's shares outstanding history. Understanding the changing numbers of AIMT shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like AIMT versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching AIMT by allowing them to research AIMT shares outstanding history as well as any other stock in our coverage universe. |
| AIMT Current Stock Quote |
Quotes delayed 20 minutes  Free AIMT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| AIMT Share Performance |
| Shares Outstanding Peers |
| Aimmune Therapeutics (AIMT) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
AIPT Shares Outstanding History AIQ Shares Outstanding History AIRS Shares Outstanding History AITB Shares Outstanding History AIXC Shares Outstanding History AKAO Shares Outstanding History AKBA Shares Outstanding History AKCA Shares Outstanding History AKER Shares Outstanding History AKRO Shares Outstanding History More Healthcare companies » |
AIMT Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
